Denali Therapeutics Inc.

EU Legislative Interests

We follow EU initiatives, policies and legislative files related to our Pharmaceuticals businesses. This includes topics such as drug research and development, clinical trials, data protection, relevant pharmaceutical legislation and initiatives, rare and neurodegenerative diseases.

Communication Activities

Mainly via participation at events and in initiatives organised by academic, patient and industry groups. For instance, Denali participated in the 2024 symposium organized by the Society for the Study of Inborn Errors of Metabolism (SSIEM) - https://www.ssiem2024.org/industry/sponsors

Interests Represented

Promotes their own interests or the collective interests of their members

Member Of

Brains for Brain Foundation, MPS Society, Society for the Study of Inborn Errors of Metabolism

Organisation Members

Collaborations are core to Denali’s strategy to develop and commercialize our portfolio. We partner with leading biopharmaceutical companies, academic institutions, foundations and enabling technology companies to advance treatments for neurodegenerative, lysosomal storage disorders and other serious diseases. We have active collaborations with Takeda, Sanofi and Biogen. Our annual report provides a comprehensive overview of Denali Therapeutics for the past year, and can be find at https://investors.denalitherapeutics.com/node/10996/html

Additional Information

This estimate includes costs attributable to covered activities, including sponsorship of events organised by academic and patient advocacy groups, and the pro-rata salary and office/administrative expenses of Denali' staff involved in representation to the European institutions, based on the proportion of employee time spent on these activities.